Interní Med. 2005; 7(6): 283-286

USE OF ALDOSTERONE ANTAGONISTS IN CARDIOLOGY

MUDr. Petr Lupínek
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

The article gives an overview on aldosterone antagonists, explains pathophysiological basics for their use in cardiology, analyses clinical indications, problems of safety and treatment monitoring.

Keywords: Key words: aldosterone antagonists, heart failure, hypertension.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lupínek P. USE OF ALDOSTERONE ANTAGONISTS IN CARDIOLOGY. Interní Med. 2005;7(6):283-286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH. Pseudo-primary aldosteronism. An entity distinct from true primary hyperaldosteronism. Circ Res 1970; 27: 203-220.
    2. Bonvalet JP, Alfaidy N, Farman N, et al. Aldosterone: intracellular receptors in human heart. Eur Heart J 1995; 16 (suppl. N): 92-97. Go to original source... Go to PubMed...
    3. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41: 211-214. Go to original source... Go to PubMed...
    4. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677. Go to original source... Go to PubMed...
    5. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002; 15: 230-235. Go to PubMed...
    6. Coirini H, Magarinos AM, De Nicola AF, et al. Further studies of brain aldosterone binding sites employing new mineralcorticoid and glucocorticoid receptor markers in vitro. Brain Res 1985; 361: 212-216. Go to original source... Go to PubMed...
    7. De Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharm Exp Ther 1987; 240: 650-656. Go to PubMed...
    8. Farquharson CAJ, Struthers AD. Aldosteron induces acute endothelial dysfunction in vivo in humans: evidence for aldosterone-induced vasculopathy. Clin Sci 2002; 103: 425-431. Go to original source... Go to PubMed...
    9. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology 2004; 217: 27-31. Go to original source... Go to PubMed...
    10. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551. Go to original source... Go to PubMed...
    11. Kornel L. Colocalization of 11 betahydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7: 100-103. Go to original source... Go to PubMed...
    12. Lim PO, Struthers AD, MacDonald TM. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 2002; 20: 11-15. Go to original source... Go to PubMed...
    13. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930. Go to original source... Go to PubMed...
    14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717. Go to original source... Go to PubMed...
    15. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    16. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838. Go to original source... Go to PubMed...
    17. Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 232-237. Go to original source... Go to PubMed...
    18. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: H1802-H1810. Go to original source... Go to PubMed...
    19. Spark RF, CM OH, Regan RM. Low-renin hypertension. Restoration of normotension and renin responsiveness Arch Intern Med 1974; 133: 205-211. Go to original source...
    20. Struthers AD, Mac Donald TM. Review of aldosterone and angiotensin II-induced target organ damage and prevention. Cardiovascular research 2004; 61: 663-670. Go to original source... Go to PubMed...
    21. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Failure 2004; 10: 297-303. Go to original source... Go to PubMed...
    22. Zelinka T. Primární hyperaldosteronismus: dignostikujeme v praxi příliš málo případů? In: Widimský J jr. a kolektiv: Arteriální hypertenze - současné klinické trendy. Triton, Praha 2004.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.